Logo


Lupin: Price erosion still a key concern

Recent acquisition & large product pipeline long-term growth drivers; price erosion in US to weigh on earnings

Lupin Pharma
Lupin Pharma

Drug major Lupin, which has been reeling under intense pricing pressure for its key products in the US, is trying to chart a growth path. Its recently announced acquisition in the US is a step in that direction. The buy will give the company access to the brand Solosec in the women’s health care segment, besides existing products such as Methergin and a few oral contraceptives (many more products are lined up for approval). The acquisition of a brand has its own benefits such as better margins and is also a long-term growth driver compared to generics that tend to face ...